Study on the use of therapeutic group 'CO2' drugs (antihypertensive) in Huelva province;Estudio de utilización de medicamentos del grupo terapéutico CO2 (antihipertensivos) en la provincia de Huelva

Pharmaceutical Care Espana

Volumn 5, Issue 1, 2003, Pages 22-28

  Díaz Paradela, Manuel ^a   Díaz Mantis, Rafael ^a   Bravo Díaz, Luis ^b   Marhueda Requena, Elisa ^b  

^a Bollullos Par del Condado ^*  (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BENAZEPRIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; HYDRALAZINE; MINOXIDIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SPIRAPRIL; TRANDOLAPRIL; VASODILATOR AGENT;

ARTICLE; DRUG CLASSIFICATION; DRUG USE; HEADACHE; HEART DISEASE; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; ORTHOSTATIC HYPOTENSION; POPULATION RESEARCH; PRESCRIPTION; SODIUM RETENTION; SPAIN; WATER RETENTION;

EID: 0037246261     PISSN: 11396202     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Consejo General de Colegios Oficiales de Farmacéuticos. Catálogo de Especialidades Farmacéuticas. Madrid, 2000.
2. Díaz Paradela M, et al. Estudios de utilización de medicamentos: revisión. Pharm Care Esp 2000; 2: 3-7.
3. Díaz Paradela M, et al. Estudios de utilización de medicamentos hipolipemiantes en la provincia de Huelva. Pharm Care Esp 2002; 4: 31-40.
4. Ball SG. The Acute Infartion Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbiditu of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-8.
5. Gavras I, et al. Drug therapy for hypertension. Am Fam Physician 1997; 55(5): 1823-34.
6. Sheps SG, et al. The Sixth Report of The Joint National Commitee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997; 157(21): 2413-46.
7. OMS. Expert Commitee. Hypertension Control. WHO Technical Report Series, number 862. Geneva, 1196. Disponible en URL: http://www.who.ch/pll/dsa/trs/trs862/en/trse862e.html.
8. Ministerio de Sanidad y Consumo. Sociedad-Liga española para la lucha contra la hipertensión arterial. Control de la hipertensión arterial en España, 1996. Madrid: IDEPSA, 1996.
9. Ministerio de Sanidad y Consumo. Grupos terapéuticos y Principios activos de mayor consumo en el Sistema Nacional de Salud durante 1997. Inf.Ter Sist Nac Salud 1999;23:144-7.
10. Catalán A. El Farmacéutico de Atención Primaria como agente dinamizador de una farmacoterapia racional. Centro de Salud 1996; 4: 431-5.
11. Philipp T, Anlauf M, Distler A, Holzgreve H, Michaelis J, Wellek S, Randomised, double blind, multicentre comparison of hydrochlorotiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. BMJ 1997; 315: 154-9.
12. Fortini A, Cappelleti C, Cechi L, Laureano R, Fosinopril in the treatment of hypertension: Effects on 24h ambulatory blood pressure and on blood pressure response to exercise. J Human Hypertens 1994; 8: 469-474.
13. Punzi HA. Safety update: focus on cough. Am J Cardiol 1993; 72: 45H-48H.
14. David D, Jallad N, Wilford Germino F, et al. A comparison of the cough profile of fosinopril and enalapril in hypertensive patients with a history of ACE inhibitor-associated cough. Am J Therap 1995; 2: 806-813.
15. Wilford Germino F, Lastra J, Pool P, et al. Evaluation of the cough profile for fosinopril in hypertensive patients with ACE inhibitor-associated cough. A pilot study. Curr Therap Res 1993; 54: 469-475.